(NASDAQ: CGEM) Cullinan Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Cullinan Oncology's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast CGEM's revenue for 2024 to be $463,571,058, with the lowest CGEM revenue forecast at $463,571,058, and the highest CGEM revenue forecast at $463,571,058. On average, 2 Wall Street analysts forecast CGEM's revenue for 2025 to be $1,916,786,754, with the lowest CGEM revenue forecast at $1,792,551,764, and the highest CGEM revenue forecast at $2,041,064,525.
In 2026, CGEM is forecast to generate $2,220,315,424 in revenue, with the lowest revenue forecast at $2,220,315,424 and the highest revenue forecast at $2,220,315,424.